Penumbra Earnings Call Transcripts
Fiscal Year 2026
-
Significant growth is expected from both thrombectomy and embolization, with new manufacturing in Costa Rica and strong clinical data from the STORM-PE trial driving adoption. The coil business is now a major growth driver, and margins are set to expand above 70% next year.
Fiscal Year 2025
-
Strong Q3 growth was driven by a focused sales force and the successful launch of Ruby XL. Clinical data from the STORM-PE trial is accelerating protocol changes and market adoption for mechanical thrombectomy, while new product iterations and regulatory progress position the company for continued expansion.
-
Q3 2025 revenue grew 17.8% year-over-year to $354.7M, led by strong U.S. thrombectomy and embolization growth, with gross margin expanding to 67.8%. Full-year revenue guidance was raised, and STORM-PE trial results are expected to drive further adoption of CAVT technology.
-
A landmark randomized trial demonstrated that mechanical thrombectomy (CABT) is superior to anticoagulation alone for intermediate high-risk pulmonary embolism, with significant improvements in heart strain and comparable safety. The results are expected to drive changes in clinical guidelines and expand adoption through education and multidisciplinary collaboration.
-
Leadership transitions and team specialization are driving focus on key growth areas. The STORM-PE trial could shift PE treatment paradigms, while new products like Thunderbolt and Ruby XL are set to accelerate adoption and innovation. Strong U.S. and improving international markets support a positive growth outlook.
-
Management outlined a strong outlook driven by innovation, new product launches, and clinical data, with Storm-PE and Thunderbolt as major upcoming catalysts. Margin expansion and reduced China headwinds are expected to support growth, while embolization and stroke franchises continue to gain share.
-
A dedicated sales force for embolization was established, enabling focus on CAVT, which has driven strong growth in VTE and stroke segments. New product launches and ongoing innovation are expanding market share, while international performance is robust, especially in Europe.
-
Q2 2025 revenue grew 13.4% year-over-year to $339.5M, led by strong U.S. thrombectomy and embolization/access performance. Gross margin was 66%, and operating income reached $40.8M. 2025 revenue guidance was raised to $1,355M–$1,370M, with continued margin expansion expected.
-
Strong innovation is fueling robust growth in thrombectomy, especially in VTE, with major share gains and optimism for continued 20%+ growth. The STORM-PE trial and Thunderbolt launch are set to drive further adoption and market impact in the coming months.
-
Innovation in clot removal is shifting from catheter improvements to computer-assisted procedures, with Thunderbolt and Flash 2.0 driving growth in neuro and VTE markets. Market share is rising, especially in DVT and PE, and margin expansion is expected to continue.
-
Mechanical thrombectomy adoption is accelerating, driven by innovative platforms and strong clinical data. International expansion, new product launches, and market access initiatives are expected to fuel growth, with margin expansion and profitability as key priorities.
-
Relentless innovation and digital transformation are driving growth, especially in thrombectomy and peripheral markets. Clinical and economic data support broader adoption, with new products like Thunderbolt and Ruby XL poised for impact. China revenue is now minimal.
-
Q1 2025 saw 16.3% revenue growth, led by U.S. thrombectomy and new product launches, with gross margin expanding to 66.6%. Guidance for 2025 remains strong despite China headwinds, with continued margin expansion and innovation expected.
-
The company is driving growth through rapid innovation in thrombectomy, leveraging CAVT technology for faster, safer procedures and expanding its product portfolio. With a large under-penetrated market, ongoing clinical studies, and a focus on profitability and international expansion, strong growth is anticipated.
Fiscal Year 2024
-
Q4 and full year 2024 saw double-digit revenue growth, led by U.S. thrombectomy and new product launches, with gross margin expansion and strong cash flow. 2025 guidance projects 12%-14% revenue growth, continued margin improvement, and U.S. thrombectomy outperformance, while China headwinds are expected to diminish.
-
2.0 and CAVT technologies are driving faster, safer clot removal and strong market adoption, with clinical trials expected to further accelerate growth in PE. New products like Lightning Bolt 6X and Thunderbolt expand the addressable market, while pricing and operational leverage remain favorable.
-
Q3 2024 revenue rose 11.1% year-over-year to $301 million, led by 21.2% U.S. thrombectomy growth and expanding gross margins. New product launches and operational efficiencies drove profitability, while international sales were impacted by China. Guidance for 2024 was reiterated, with raised U.S. thrombectomy growth expectations.
-
Recent product launches have improved clot removal speed and safety, driving market expansion and share gains, especially in underpenetrated segments. New products targeting below-the-knee arteries and additional CAVT devices are set to launch soon, supporting a strong growth outlook for 2025 and beyond.
-
Management is focused on expanding thrombectomy access and driving growth through product innovation, with new launches targeting peripheral and neurovascular markets. Recent headwinds are expected to subside, and strong clinical and economic feedback supports continued adoption.
-
The business is undergoing a transformation, driven by innovative CAVT technology and a reset financial strategy, including a $200 million share buyback. Growth is expected to accelerate in 2025 and beyond, supported by new product launches and strong market positioning.
-
Q2 2024 revenue grew 14.5% year-over-year, led by 25% growth in thrombectomy. Guidance for 2024 was reduced due to China headwinds and delayed European launches, but margin expansion and strong product momentum are expected to continue. Cash position remains strong with no debt.
-
CAVT technology is accelerating growth in thrombectomy, with Flash and Bolt products driving significant share gains in VTE and arterial markets. The business targets a 15-16% CAGR over five years, focusing on market expansion, share gains, and innovation, with global opportunities dependent on reimbursement.
-
The conference highlighted a strategic shift to thrombectomy, embolization, and access, with new technologies like Lightning Flash 2.0 driving faster, safer procedures. Strong market leadership, ongoing innovation, and a focus on education and competition position the business for significant growth.